Activin receptor type IIA variants and methods of use thereof
AssigneeKeros Therapeutics, Inc.
InventorsJasbir S. Seehra, Jennifer Lachey
Life of this patent
Estimating the term…
Abstract
The invention features polypeptides that include an extracellular ActRIIa variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRIIa variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving weakness and atrophy of muscles, e.g., Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, inclusion body myositis, amyotrophic lateral sclerosis, sarcopenia; or cancer cachexia; or metabolic diseases, e.g., obesity, Type-1 diabetes, or Type-2 diabetes.
Claims6
A polypeptide comprising, from N-terminus to C-terminus, an extracellular activin receptor type IIa (ActRIIA) variant, a linker, and an Fc domain, wherein the variant has the sequence of SEQ ID NO:
- 69 and the linker is a GGG linker.
Dependencies are inferred from the claim text.